Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.

MLA

Kratochwil, Clemens, et al. “Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.” Journal of Nuclear Medicine, vol. 58, no. 10, Oct. 2017, pp. 1624–31. EBSCOhost, https://doi.org/10.2967/jnumed.117.191395.

APA

Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017). Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. Journal of Nuclear Medicine, 58(10), 1624–1631. https://doi.org/10.2967/jnumed.117.191395

Chicago

Kratochwil, Clemens, Frank Bruchertseifer, Hendrik Rathke, Marcus Bronzel, Christos Apostolidis, Wilko Weichert, Uwe Haberkorn, Frederik L. Giesel, and Alfred Morgenstern. 2017. “Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.” Journal of Nuclear Medicine 58 (10): 1624–31. doi:10.2967/jnumed.117.191395.